NCT06812585CompletedPhase 2
The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study
Source: ClinicalTrials.gov · Last updated 6 Feb 2025
Brief summary (registry, in English)
This pilot study aims to investigate the tolerability and feasibility of using metformin as an adjuvant treatment for RRMS. Also, it aims to evaluate the preliminary evidence of its efficacy by analyzing outcomes related to immunology, clinical manifestations, and radiological findings.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 2 Feb 2025
- Start date
- 1 Apr 2022
- Primary completion date
- 30 May 2023
- Lead sponsor
- German University in Cairo
- Diseases
- Multiple sclerosis
- NCT number
- NCT06812585
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- From 1 Apr 2022 to the primary completion date, 30 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Additionally, patients who had undergone corticosteroids before or within 4 weeks of the study's commencement were ineligible for participation.
Other illness
- Individuals taking metformin or other diabetes medications, pregnant, and breastfeeding females were excluded.
- Those with congestive heart failure, liver impairment, kidney dysfunction, or chronic respiratory conditions were not eligible to participate.
Who the study is looking for
- Individuals between 18 and 50 years of age who met the 2017 McDonald criteria were recruited.
- Patients with RRMS and had an EDSS score below 7.0.
- Participants were required to have been on a stable IFNβ-1a regimen for at least six months before the commencement of the study.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nasser Institute for Research and Treatment. Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.